What is the estimated worth of the AI in drug repurposing market?

The market revenue for AI in drug repurposing is anticipated at USD 1.92 billion in 2027.

How will the AI in drug repurposing industry grow in terms of size and CAGR by 2036?

AI in Drug Repurposing Market size was worth USD 1.57 billion in 2026 and is expected to grow at a 24.99% CAGR between 2027 and 2036, crossing USD 14.61 billion by 2036.

How is AI-assisted discovery accelerating drug repurposing workflows?

AI enables faster analysis of biological relationships, therapeutic targets, disease mechanisms, and existing drug candidates, helping researchers identify previously unrecognized connections and prioritize promising repurposing opportunities for further investigation.

How are multimodal datasets strengthening AI-driven drug repurposing strategies?

Interconnected biological, molecular, clinical, and real-world datasets provide broader analytical inputs, helping AI models identify relationships between existing therapies and emerging indications while supporting more comprehensive repurposing candidate identification.

Why do software and platforms dominate the AI in drug repurposing market?

Software and platforms held 63.97% of the market in 2026, driven by their ability to integrate biomedical datasets, automate candidate screening, and accelerate evidence-based identification of new therapeutic applications.

How are generative AI and large language models expanding drug repurposing opportunities?

Generative AI and LLMs are the fastest-growing technology segment, helping researchers synthesize scientific literature, interpret clinical documentation, and identify therapeutic hypotheses across diverse biomedical information sources.

How does North America maintain its leadership in AI-driven drug repurposing?

North America accounted for 54.44% market share in 2026, driven by advanced pharmaceutical research, strong AI adoption, and investment in technologies that improve drug discovery efficiency and therapeutic candidate identification.

What is driving the rapid expansion of AI in drug repurposing across Asia Pacific?

Asia Pacific is expected to grow fastest as AI investment, pharmaceutical research capabilities, healthcare digitalization, and computational infrastructure expand opportunities for identifying new applications for existing therapies.

What are the prominent companies operating in the AI in drug repurposing landscape?

Top companies in the AI in drug repurposing market include BenevolentAI (UK), Insilico Medicine (Hong Kong), Exscientia (UK), Atomwise (USA), Recursion Pharmaceuticals (USA), XtalPi (China), Cyclica (Canada), Healx (UK), DeepCure (USA), Schrödinger (USA).